60 likes | 71 Views
Market Size u2013 USD 7.39 billion in 2018, Market Growth u2013 CAGR of 7.3%, Market Trends u2013 Product Launches and Research for Advanced Tech Developments
E N D
Diabetic Retinopathy Market to Reach USD 13.04 billion By 2026
Market Summary Market Size – USD 7.39 billion in 2018, Market Growth – CAGR of 7.3%, Market Trends – Product Launches and Research for Advanced Tech Developments Based on current analysis, the global diabetic retinopathy market was valued at USD 7.39 billion in 2018 and is expected to reach USD 13.04 billion by 2026, at a CAGR of 7.3%. Diabetic retinopathy is a diabetes obstacle that affects eyes. It's caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). • Further key findings from the report suggest • Asia-Pacific regional segment of the diabetic retinopathy market is expected to register itself as highest growing segment during the forecasted period, at a CAGR of 8.3%; owing it to the qualitative as well as quantitative market potential offered in developing nations such as China & India • Non-proliferative diabetic retinopathy has registered highest CAGR of 7.5% and is successful in dominating the market with market share of 56%. The most common reason for blindness in people suffering from diabetes is non-proliferative • According to the estimates of the screening conducted by the All India Ophthalmological Society, the prevalence of diabetic retinopathy in the data set collected by them was approximately calculated to 21.7% www.reportsanddata.com
Market Summary Key Players: Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Novartis AG, Valeant Pharmaceuticals International Inc., Abbott Laboratories Ltd., Alimera Sciences Inc., AmPio Pharmaceuticals Inc., Bausch & Lomb Inc., BoehringerIngelheim GmbH, iCo Therapeutics Inc., Lupin Ltd., PAREXEL International Corp., Quark Pharmaceuticals Inc., Thrombogenic NV, and Vitreoretinal Technologies Inc Segmentation: Type (Revenue in USD Million; 2016–2026) Proliferative diabetic retinopathy Non-proliferative diabetic retinopathy Mild Moderate Severe Management (Revenue in USD Million; 2016–2026) Anti-VEGF Intraocular steroid injection Laser surgery Vitrectomy To look at the PDF Sample Report and get 30 minutes of a free consultation @https://www.reportsanddata.com/sample-enquiry-form/1484 www.reportsanddata.com
Market Summary • Distribution channel (Revenue in USD Million; 2016–2026) • Eye clinics • Hospital and pharmacies • Ambulatory surgical centers • Other • Regional Outlook (Revenue in USD Million; 2016–2026): • North America (United States, Canada, and Mexico) • Europe (Germany, France, UK, Russia, and Italy) • Asia-Pacific (China, Japan, Korea, India, and Southeast Asia) • South America (Brazil, Argentina, Colombia, etc.) • Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa) Grab Your Report at an Impressive Discount! Please Click Here : @https://www.reportsanddata.com/discount-enquiry-form/1484 www.reportsanddata.com
The report emphasizes the following key questions: Q.1.What are the most lucrative and promising growth prospects for the market? Q.2.Which sectors are expected to deliver a high growth rate and which industry aspects come into play in this advancement? Q.3.Which geographies are estimated to exhibit the highest growth and the underlying causes? Q.4.Which factors are impacting the future of the market and what are the driving factors? Q.5.What are the hurdles and challenges curtailing the industry’s growth in the forecast period? www.reportsanddata.com
About Us Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact Us: John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com